Release Date: August 20, 2024
Expiration Date: August 20, 2025
Activity Overview
This video-based program is designed for health care professionals to explore strategies for individualizing care in patients with hemophilia A through a unique perspective, putting the patient voice front and center. A patient will lend their expertise to this program by sharing their journey living with hemophilia A. This online activity focuses on the burden of hemophilic arthropathy and current and emerging treatment options for prevention of synovitis, with a focus on how to personalize care for optimal outcomes.
Target Audience
This educational activity is directed toward hematologists, primary care physicians, specialty NPs, PAs, RNs, and other HCPs that manage patients with Hemophilia A.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the burden of disease of hemophilic arthropathy on patients with hemophilia A
- Summarize approaches to identifying patients with hemophilia who are at high risk for joint damage
- Evaluate clinical trial data for current and emerging treatment options for the prophylactic care of patients with hemophilia A
- Formulate individualized prophylactic treatment plans to reduce the risk of hemophilic arthropathy for patients with hemophilia
Stacy E. Croteau, MD, MMS
Director Hemophilia/VWD program | Boston Children’s Hospital
Medical Director | Boston Bleeding Disorders Center
Assistant Professor of Pediatrics | Harvard Medical School
Boston, MA
Disclosures: Consultant: BioMarin, Sanofi: Research Support: Sanofi, Spark Therapeutics.
Fernando F. Corrales-Medina, MD, FAAP
Associate Professor of Clinical Pediatrics
Medical Co-Director, Pediatric Hemophilia Program
Director, Pediatric Hematology-Oncology Fellowship Program
University of Miami-Comprehensive Hemophilia Treatment Center
Division of Pediatric Hematology-Oncology
University of Miami-Miller School of Medicine
Miami, FL
Disclosures: Grant/Research Support: Bayer, Octapharma: Advisory Board; Genetech, Sanofi, Novo-Nordisk; Other: Biomarin
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
